We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
-5.2%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$176M
AUM Growth
-$3.89M
(-2.2%)
Cap. Flow
+$11.2M
Cap. Flow
% of AUM
6.35%
Top 10 Holdings %
Top 10 Hldgs %
22.1%
Holding
256
New
24
Increased
39
Reduced
133
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
WBA
Walgreens Boots Alliance
WBA
|
+$3.86M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$3.65M |
| 3 |
TSVT
2seventy bio
TSVT
|
+$3.13M |
| 4 |
uniQure
QURE
|
+$3.1M |
| 5 |
Embecta
EMBC
|
+$2.13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AdaptHealth
AHCO
|
+$3.44M |
| 2 |
Elanco Animal Health
ELAN
|
+$2.97M |
| 3 |
Centene
CNC
|
+$2.7M |
| 4 |
iShares MBS ETF
MBB
|
+$2.05M |
| 5 |
Lantheus
LNTH
|
+$1.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.71% |
| 2 | Real Estate | 10.29% |
| 3 | Financials | 3.55% |
| 4 | Technology | 3.29% |
| 5 | Energy | 2.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MFA
26
MFA Financial
MFA
$960M
| $1.95M | 1.1% |
202,725
+15,000
| +8% | +$162K |
|
27
Kiniksa Pharmaceuticals
KNSA
$4.92B
| $1.91M | 1.08% |
110,000
| – | – |
|
28
GSK
GSK
$104B
| $1.81M | 1.03% |
50,000
| – | – |
|
|
ADAM
29
Adamas Trust
ADAM
$807M
| $1.71M | 0.97% |
200,963
+15,000
| +8% | +$142K |
|
|
DCPH
30
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $1.68M | 0.95% |
132,000
+54,500
| +70% | +$752K |
|
|
COOP
31
DELISTED
Mr. Cooper
COOP
| $1.68M | 0.95% |
31,290
-10,000
| -24% | -$550K |
|
32
Phathom Pharmaceuticals
PHAT
$873M
| $1.66M | 0.94% |
160,000
+30,000
| +23% | +$412K |
|
|
DVAX
33
DELISTED
Dynavax Technologies
DVAX
| $1.62M | 0.92% |
110,000
| – | – |
|
|
FOLD
34
DELISTED
Amicus Therapeutics
FOLD
| $1.61M | 0.91% |
132,500
| – | – |
|
35
Karyopharm Therapeutics
KPTI
$216M
| $1.51M | 0.85% |
75,000
+21,000
| +39% | +$471K |
|
36
BioMarin Pharmaceuticals
BMRN
$11.5B
| $1.46M | 0.83% |
16,500
| – | – |
|
37
Immunovant
IMVT
$8.27B
| $1.46M | 0.83% |
+38,000
| New | +$859K |
|
38
argenx
ARGX
$53.8B
| $1.35M | 0.77% |
2,750
+500
| +22% | +$245K |
|
|
ITCI
39
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.33M | 0.75% |
25,500
| – | – |
|
40
MGIC Investment
MTG
$6.23B
| $1.32M | 0.75% |
79,379
-34,521
| -30% | -$587K |
|
41
Equity Lifestyle Properties
ELS
$12.8B
| $1.31M | 0.74% |
20,611
+12,500
| +154% | +$844K |
|
|
KALV
42
DELISTED
KalVista Pharmaceuticals
KALV
| $1.3M | 0.74% |
135,000
| – | – |
|
|
MOR
43
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $1.24M | 0.71% |
185,000
| – | – |
|
44
Viridian Therapeutics
VRDN
$1.99B
| $1.23M | 0.7% |
80,000
+44,500
| +125% | +$849K |
|
45
Verastem
VSTM
$530M
| $1.22M | 0.69% |
150,000
| – | – |
|
46
Alkermes
ALKS
$8.79B
| $1.19M | 0.68% |
42,500
+7,500
| +21% | +$220K |
|
|
BCYC
47
Bicycle Therapeutics
BCYC
$294M
| $1.18M | 0.67% |
+58,500
| New | +$1.34M |
|
|
DAWN
48
DELISTED
Day One Biopharmaceuticals
DAWN
| $1.17M | 0.66% |
95,000
-15,000
| -14% | -$196K |
|
|
MITT
49
TPG Mortgage Investment Trust
MITT
$243M
| $1.16M | 0.66% |
208,879
+104,058
| +99% | +$660K |
|
50
Enact Holdings
ACT
$6.49B
| $1.15M | 0.65% |
42,367
| – | – |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q3 2023 Portfolio in Review
As of Q3 2023, AlphaCentric Advisors held 256 positions worth $176M, down 2.2% from $180M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
AlphaCentric Advisors deployed $11.2M of net new capital in Q3 2023, opening 24 new positions and adding to 39 existing holdings. Its largest new stake was Revance Therapeutics, Inc.: 190,000 shares worth $2.18M.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 60% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $1.9M trimmed.
- AlphaCentric Advisors's largest Q3 2023 buy was Revance Therapeutics, Inc.: 190,000 shares worth $2.18M.
- AlphaCentric Advisors added most to Walgreens Boots Alliance in Q3 2023, an estimated $3.86M increase.
- AlphaCentric Advisors's biggest Q3 2023 reduction was Jazz Pharmaceuticals, cutting an estimated $1.9M.
- AlphaCentric Advisors fully exited AdaptHealth in Q3 2023, selling an estimated $3.44M.
- AlphaCentric Advisors's ten largest holdings make up 22% of its $176M portfolio in Q3 2023.
- AlphaCentric Advisors opened 24 new positions and closed 21 in Q3 2023.
- AlphaCentric Advisors's portfolio value fell 2.2% quarter-over-quarter to $176M.
Based on AlphaCentric Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.